Xconomy’s EXOME Presents: What’s Hot in Boston Biotech

After an unprecedented multi-year bull run, biotech is facing headwinds once again. Drug companies have become a target in an election year, putting pricing strategies under a microscope. Valuations have tumbled, drying up a fertile ground for IPOs. Yet biotech innovation continues apace, particularly in Boston. New ways of harnessing the immune system to battle cancer are being unlocked. Investments in neuroscience, long a drug development minefield, have picked up. Biotechs are taking aim at a dangerous liver disease that looms as a potential nationwide epidemic. And local venture firms are armed with new funds to spend on startups.

What ideas are innovators focusing on? What hurdles do they have to cross? And how, in a more challenging environment, can those ideas best move forward?

Join Xconomy as we bring together a group of Boston biotech’s top entrepreneurs, investors, and leaders to explore these, and other topics on the local life sciences horizon.

Confirmed Speakers:

Phillip A. Sharp, Nobel Laureate; Institute Professor, MIT
Bruce Booth, Partner, Atlas Venture
Don Nicholson, CEO, Nimbus Therapeutics
Deborah Dunsire, CEO, Forum Pharmaceuticals
Gregory Verdine, Founder & CSO, Warp Drive Bio; Professor, Harvard University
Al Sandrock, EVP & Chief Medical Officer, Biogen
Peter Hecht, CEO, Ironwood Pharmaceuticals
Jens Eckstein, President, SR One
Peter Kolchinsky, Founder & Managing Director, RA Capital
Nir Hacohen, Co-founder, Neon Therapeutics; Director, MGH Center for Immunotherapy
Cary Pfeffer, Interim CEO, Neon Therapeutics; Partner, Third Rock Ventures
Daphne Zohar, CEO, Puretech Health
Samantha Singer, COO, The Broad Institute
Robert Urban, Head, Johnson & Johnson Innovation, Boston
Tillman U. Gerngross, Professor of Bioengineering, Dartmouth College